Semaglutide vs Tirzepatide: evidence, safety and FDA status
PepsRadar · Comparison · AI-assisted, written from the checked facts on each profile · Content updated (how dates work) · Not reviewed by a medical professional
The short answer
Both are FDA-approved prescription medicines, sold under specific brand names for type 2 diabetes and weight management. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on both the GIP and GLP-1 receptors. In SURPASS-2, a head-to-head trial in 1,879 people with type 2 diabetes, tirzepatide lowered HbA1c and weight more than the semaglutide dose used in that trial.
Key differences
Targets: semaglutide works through one receptor (GLP-1); tirzepatide through two (GIP and GLP-1).
In their main obesity trials, average weight loss was 14.9% with semaglutide (STEP 1) and 15.0–20.9% across tirzepatide groups (SURMOUNT-1), against 2.4% and 3.1% with placebo. These were separate trials with different people, so the numbers are not a direct contest.
Heart outcomes: semaglutide’s profile includes SELECT (heart attack, stroke or cardiovascular death in 6.5% versus 8.0% with placebo, in people with heart disease and without diabetes). Tirzepatide’s profile does not yet summarize a heart outcomes trial, which is a gap in our coverage, not evidence either way.
Both labels carry the same boxed warning about thyroid C-cell tumors in rodents, and both warn of pancreatitis and gallbladder disease.
Semaglutide is an incretin medicine with product-specific uses in diabetes, weight management, and other defined conditions. Brand and formulation matter.
Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.
Human evidence
4 randomized trials
3 randomized trials
Human safety data
FDA label. Semaglutide is a widely used GLP-1 drug; stomach side effects are common, and the label warns of thyroid C-cell tumors in rodents, pancreatitis, gallbladder disease and diabetic eye complications.
FDA label. Tirzepatide is a GIP/GLP-1 drug for weight and diabetes; stomach side effects are common, and the label warns of thyroid C-cell tumors in rats, pancreatitis, gallbladder disease and kidney injury.
Boxed warning
Caused thyroid C-cell tumors in rodents; it is unknown whether it does in humans. Do not use with a personal or family history of medullary thyroid carcinoma or with MEN 2.
Caused thyroid C-cell tumors in rats; it is unknown whether it does in humans. Do not use with a personal or family history of medullary thyroid carcinoma or with MEN 2.
Serious risks
Acute pancreatitis
Worsening diabetic eye disease (retinopathy)
Kidney injury from dehydration
Severe stomach and bowel side effects
Gallbladder disease
Serious allergic reactions, and inhaling stomach contents during anesthesia or deep sedation
Severe stomach and bowel side effects
Kidney injury from dehydration
Gallbladder disease
Acute pancreatitis
Serious allergic reactions, including anaphylaxis and angioedema
Low blood sugar with insulin or sulfonylureas, and inhaling stomach contents during anesthesia
False: Research-labeled GLP-1 peptides sold online, including coded names like 'GLP3-R', 'R', 'GLP1-S' or 'GLP2-T', are the same as retatrutide, Ozempic or Mounjaro.
False: Research-labeled GLP-1 peptides sold online, including coded names like 'GLP3-R', 'R', 'GLP1-S' or 'GLP2-T', are the same as retatrutide, Ozempic or Mounjaro.
Each row comes from the Semaglutide and Tirzepatide profiles, where every fact links to its source. “Conditions flagged” lists the health conditions each profile’s Risks & interactions section mentions.
The human studies
Semaglutide
STEP 1 (2021)
Human randomized trial · 1,961 adults with obesity, or overweight with a weight-related condition, without diabetes.
Mean weight change was −14.9% versus −2.4%, a 12.4-percentage-point estimated difference. Gastrointestinal effects were common.
Limitation: These are average results for a specific injectable regimen and trial population. The study is not a comparison with tirzepatide and cannot validate compounded or research-use products.
Human randomized trial · 3,533 adults with type 2 diabetes and chronic kidney disease.
Major kidney disease events (kidney failure, a fall in kidney function of at least half, or death from kidney or cardiovascular causes) were 24% lower with semaglutide (hazard ratio 0.76). Death from cardiovascular causes and from any cause were also lower, and serious adverse events were slightly less common (49.6% vs 53.8%).
Limitation: Applies to people with type 2 diabetes and established kidney disease. Trials stopped early for benefit can overstate the effect, and the trial says nothing about people without diabetes or about research-use products.
Human randomized trial · 17,604 adults aged 45 or older with established cardiovascular disease, BMI at least 27, and no history of diabetes.
Cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. Hazard ratio 0.80 (95% CI 0.72–0.90). Adverse events led to permanent treatment discontinuation in 16.6% versus 8.2%.
Limitation: This population already had cardiovascular disease. The result does not establish the same benefit in every person seeking weight loss or validate unregulated preparations. Funded by Novo Nordisk.
Human randomized withdrawal trial · 803 adults without diabetes who completed a 20-week semaglutide run-in and reached the studied maintenance regimen; 902 initially entered run-in.
From randomization at week 20 to week 68, weight changed by −7.9% with continued semaglutide versus +6.9% after switching to placebo. Gastrointestinal events occurred in 49.1% versus 26.1%.
Limitation: People unable to reach the regimen during run-in were not randomized. This selected population limits generalization to everyone starting treatment. It is not a trial of tapering or an individualized stopping strategy.
Human randomized trial · 2,539 adults with obesity, or overweight and a weight-related complication, without diabetes.
Mean weight reductions were 15.0%, 19.5%, and 20.9% across active groups versus 3.1% with placebo. Gastrointestinal effects were common.
Limitation: This trial cannot be compared directly with STEP 1 as if participants were randomized between the two drugs. Outcomes depend on population, duration, regimen, and handling of discontinuation.
SURPASS-2 direct comparison in type 2 diabetes (2021)
Human randomized trial · 1,879 patients with type 2 diabetes; mean baseline HbA1c 8.28%.
Mean HbA1c fell by 2.01–2.30 percentage points in the tirzepatide groups and 1.86 with semaglutide. Weight reductions were greater with tirzepatide; between-group differences ranged from 1.9 to 5.5 kg. Gastrointestinal adverse effects were common.
Limitation: Open-label design; the semaglutide comparator was its diabetes dose, not the higher weight-management dose. It is not a universal ranking across all products or doses. Funded by Eli Lilly.
SURMOUNT-4 · continuation versus withdrawal (2024)
Human randomized withdrawal trial · 670 adults with overweight or obesity without diabetes who completed a 36-week open-label lead-in; 783 initially enrolled.
After a mean 20.9% reduction during lead-in, weight changed by −5.5% with continued treatment versus +14.0% with placebo from week 36 to week 88. At least 80% of the lead-in loss was maintained by 89.5% versus 16.6%.
Limitation: Only lead-in completers were randomized. Gastrointestinal events were more common with continued treatment. This does not determine an individual stopping plan or prove that every patient will regain the same amount.
Results from different trials are not a head-to-head comparison: the people, preparations, durations and measures differ.
Bottom line
Which one fits is a prescriber’s decision, based on the label, your other conditions and coverage. Research-market “GLP-1” vials are not these medicines, and PepsRadar does not list them.
PepsRadar does not give doses or usage instructions, and this page is not medical advice. For a prescription medicine, talk to your prescriber or pharmacist.
Plain-English summaries of new peptide studies, regulatory news and notable price changes from the sellers we track. No dosing advice. Unsubscribe anytime.
Peps